The International Generic and Biosimilar Medicines Association is an international organization of national and regional associations representing manufacturers of generic and biosimilar medicines from around the world. Our industry supplies an estimated 80% of all quality-assured medicines globally and is therefore absolutely critical to ensuring safe and affordable medicines are available to patients worldwide and indispensable for achieving Universal Health Coverage.
Fight the Fakes Alliance calls for a watertight global medicines supply chain.
IGBA Reiterates its Yearly Call to Join the Biosimilars Movement on Advancing Access (November 2022)
Geneva, November 14, 2022 – In the week ahead, IGBA will renew its commitment to the collaborative effort to establish worldwide biosimilar policies that deliver better health outcomes and biologics access equity for more patients. The third Global Biosimilars Week will run from 14th to 18th November, 2022 on social media, supported by a rich resource dedicated website globalbiosimilarsweek.org.
- IGBA’s CEO Advisory Committee Meets with WHO Director General and WHO Leadership (October 2022)
- Richard Saynor and Vinita Gupta appointed Chair and Vice-Chair of IGBA CEO Advisory Committee (October 2022)
- Global Biosimilars Week: Message of Vivian Frittelli, Chair, IGBA (October 2022)
- WHO-South Korea biomanufacturing training hub initiative (September 2022)
